Literature DB >> 34044876

The emerging role of RNA N6-methyladenosine methylation in breast cancer.

Fangchao Zheng1, Feng Du2, Jiuda Zhao3, Xue Wang4, Yiran Si1, Peng Jin5, Haili Qian6, Binghe Xu1, Peng Yuan7,8.   

Abstract

N6-methyladenosine (m6A) modification is the most prevalent internal mRNA modification and is involved in many biological processes in eukaryotes. Accumulating evidence has demonstrated that m6A may play either a promoting or suppressing role in breast cancer, including in tumorigenesis, metastasis and angiogenesis. In this review, we summarize the latest research progress on the biological function and prognostic value of m6A modification in breast cancer, as well as potential related therapeutic strategies.

Entities:  

Keywords:  Breast cancer; Clinicopathological features; Drug target; Prognosis; RNA methylation

Year:  2021        PMID： 34044876     DOI： 10.1186/s40364-021-00295-8

Source DB:  PubMed          Journal:  Biomark Res        ISSN： 2050-7771


  104 in total

1.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Authors:  Jennifer K Litton; Hope S Rugo; Johannes Ettl; Sara A Hurvitz; Anthony Gonçalves; Kyung-Hun Lee; Louis Fehrenbacher; Rinat Yerushalmi; Lida A Mina; Miguel Martin; Henri Roché; Young-Hyuck Im; Ruben G W Quek; Denka Markova; Iulia C Tudor; Alison L Hannah; Wolfgang Eiermann; Joanne L Blum
Journal:  N Engl J Med       Date:  2018-08-15       Impact factor: 91.245

2.  Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.

Authors:  Kenji Tamura; Junji Tsurutani; Shunji Takahashi; Hiroji Iwata; Ian E Krop; Charles Redfern; Yasuaki Sagara; Toshihiko Doi; Haeseong Park; Rashmi K Murthy; Rebecca A Redman; Takahiro Jikoh; Caleb Lee; Masahiro Sugihara; Javad Shahidi; Antoine Yver; Shanu Modi
Journal:  Lancet Oncol       Date:  2019-04-29       Impact factor: 41.316

3.  Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Fabrice André; Eva Ciruelos; Gabor Rubovszky; Mario Campone; Sibylle Loibl; Hope S Rugo; Hiroji Iwata; Pierfranco Conte; Ingrid A Mayer; Bella Kaufman; Toshinari Yamashita; Yen-Shen Lu; Kenichi Inoue; Masato Takahashi; Zsuzsanna Pápai; Anne-Sophie Longin; David Mills; Celine Wilke; Samit Hirawat; Dejan Juric
Journal:  N Engl J Med       Date:  2019-05-16       Impact factor: 91.245

4.  Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.

Authors:  Tomohiro Ochi; Giampaolo Bianchini; Michiko Ando; Fumi Nozaki; Daiki Kobayashi; Carmen Criscitiello; Giuseppe Curigliano; Takayuki Iwamoto; Naoki Niikura; Hiroyuki Takei; Atsushi Yoshida; Junko Takei; Koyu Suzuki; Hideko Yamauchi; Naoki Hayashi
Journal:  Eur J Cancer       Date:  2019-07-11       Impact factor: 9.162

5.  Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

Authors:  Aditya Bardia; Ingrid A Mayer; Linda T Vahdat; Sara M Tolaney; Steven J Isakoff; Jennifer R Diamond; Joyce O'Shaughnessy; Rebecca L Moroose; Alessandro D Santin; Vandana G Abramson; Nikita C Shah; Hope S Rugo; David M Goldenberg; Ala M Sweidan; Robert Iannone; Sarah Washkowitz; Robert M Sharkey; William A Wegener; Kevin Kalinsky
Journal:  N Engl J Med       Date:  2019-02-21       Impact factor: 91.245

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer.

Authors:  Woosung Chung; Hye Hyeon Eum; Hae-Ock Lee; Kyung-Min Lee; Han-Byoel Lee; Kyu-Tae Kim; Han Suk Ryu; Sangmin Kim; Jeong Eon Lee; Yeon Hee Park; Zhengyan Kan; Wonshik Han; Woong-Yang Park
Journal:  Nat Commun       Date:  2017-05-05       Impact factor: 14.919

8.  Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.

Authors:  Rajendra Bahadur Shahi; Sylvia De Brakeleer; Ben Caljon; Ingrid Pauwels; Maryse Bonduelle; Sofie Joris; Christel Fontaine; Marian Vanhoeij; Sonia Van Dooren; Erik Teugels; Jacques De Grève
Journal:  BMC Cancer       Date:  2019-04-04       Impact factor: 4.430

9.  Epigenome-wide DNA methylation and risk of breast cancer: a systematic review.

Authors:  Kaoutar Ennour-Idrissi; Dzevka Dragic; Francine Durocher; Caroline Diorio
Journal:  BMC Cancer       Date:  2020-10-31       Impact factor: 4.430

10.  Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.

Authors:  Neil A O'Brien; Martina S J McDermott; Dylan Conklin; Tong Luo; Raul Ayala; Suruchi Salgar; Kevin Chau; Emmanuelle DiTomaso; Naveen Babbar; Faye Su; Alex Gaither; Sara A Hurvitz; Ronald Linnartz; Kristine Rose; Samit Hirawat; Dennis J Slamon
Journal:  Breast Cancer Res       Date:  2020-08-14       Impact factor: 6.466
View more
  6 in total

Review 1.  Cancer stem cells: a major culprit of intra-tumor heterogeneity.

Authors:  Faiza Naz; Mengran Shi; Salvia Sajid; Zhao Yang; Changyuan Yu
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

2.  Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours.

Authors:  Zhelin Xia; Fanhua Kong; Kunpeng Wang; Xin Zhang
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

3.  YTHDF1 promotes breast cancer progression by facilitating FOXM1 translation in an m6A-dependent manner.

Authors:  Hengyu Chen; Yuanhang Yu; Ming Yang; Haohao Huang; Shenghui Ma; Jin Hu; Zihan Xi; Hui Guo; Guojie Yao; Liu Yang; Xiaoqing Huang; Feng Zhang; Guanghong Tan; Huangfu Wu; Wuping Zheng; Lei Li
Journal:  Cell Biosci       Date:  2022-02-23       Impact factor: 7.133

4.  Emerging Roles of m6A RNA Methylation Regulators in Gynecological Cancer.

Authors:  Wanjun Huang; Fanhua Kong; Ruolan Li; Xiang Chen; Kunpeng Wang
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244

5.  Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.

Authors:  Yong Liu; Guangbing Li; Yang Yang; Ziwen Lu; Tao Wang; Xiaoyu Wang; Jun Liu
Journal:  Front Genet       Date:  2022-01-03       Impact factor: 4.599

6.  Dissecting the Role of N6-Methylandenosine-Related Long Non-coding RNAs Signature in Prognosis and Immune Microenvironment of Breast Cancer.

Authors:  Jinguo Zhang; Benjie Shan; Lin Lin; Jie Dong; Qingqing Sun; Qiong Zhou; Jian Chen; Xinghua Han
Journal:  Front Cell Dev Biol       Date:  2021-10-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.